Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, facing scrutiny over internal control issues despite its industry advantages and market position [1] Group 1: Company Overview - Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences sector, focusing on clinical trial temperature-controlled supply chain services [2] - The company achieved revenues of 614 million yuan, 654 million yuan, and 538 million yuan for the years 2023, 2024, and the first three quarters of 2025, respectively, with profits of 92.03 million yuan, 26.396 million yuan, and 113 million yuan during the same periods [2] - The revenue structure is primarily derived from clinical trial temperature-controlled supply chain services, which consistently account for over 80% of total revenue [2] Group 2: Market Dynamics - The growth in Shanghai Shengsheng's performance is driven by the expanding market size and technological demands, with the clinical trial temperature-controlled service market in China growing from 2 billion yuan in 2020 to 3.6 billion yuan in 2024 [3] - The company holds both GMP and GDP certifications, establishing a nationwide service network to meet the stringent temperature control and safety requirements of the pharmaceutical industry [3] Group 3: Financial Performance and Challenges - The accounts receivable of Shanghai Shengsheng increased significantly, with trade receivables of 157 million yuan, 192 million yuan, and 220 million yuan during the reporting period, and the turnover days for trade receivables were 98 days, 98 days, and 105 days, respectively [4] - The company acknowledged that some transactions with clients are settled on credit, which could adversely affect its cash flow and business operations if clients fail to pay on time [4] Group 4: Governance Issues - Concerns regarding internal control governance arose when the actual controllers borrowed funds to increase their shareholding and subsequently transferred shares at a premium, raising regulatory scrutiny [5] - The significant difference in share transfer prices has led to questions from regulators, although the company has stated that there are reasonable backgrounds for these price variations [5] - In 2024, the company reported a substantial drop in profits primarily due to share-based payment expenses amounting to 72.12 million yuan, with a significant portion of these expenses attributed to a few high-salaried employees [6]

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange after previously withdrawing its application from the Shanghai Stock Exchange in June 2024 [1] Group 1: Company Overview - Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry, focusing on clinical trial temperature-controlled supply chain services and extending to commercialized medical product temperature-controlled supply chain services [2] - The company is ranked as the number one temperature-controlled supply chain service provider in China and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers [2] - The company has served over 7,000 clients, including top biopharmaceutical and biotechnology companies, central laboratories, CROs, and CDMOs [2] Group 2: Operational Capabilities - Shanghai Shengsheng possesses both GMP and GDP qualifications and has established a service network across major cities in China, with over 130 operational sites and more than 40 regional operation centers, covering 99% of prefecture-level cities [3] - The company has also set up regional operation centers in overseas markets, providing services in over 70 countries and regions [3] Group 3: Financial Performance - The company reported revenues of 614.2 million RMB and 654.5 million RMB for the years 2023 and 2024, respectively, with profits of 92.0 million RMB and 26.4 million RMB [4] - For the first three quarters of 2025, the company achieved a revenue of 538.7 million RMB, representing a year-on-year growth of 10.97%, and a profit of 113.0 million RMB, reflecting a year-on-year increase of 68.6% [4] Group 4: Use of IPO Proceeds - The funds raised from the IPO will be used to expand and upgrade the company's domestic and international supply chain service network, enhance temperature control technology and digital capabilities, and support potential strategic investments and acquisitions [4]

Group 1 - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1]

Group 1 - The core viewpoint of the article is that Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guotai Junan Securities (Hong Kong) as joint sponsors [1] - Shanghai Shengsheng is recognized as a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry in China, focusing on temperature-controlled supply chain services for clinical trials and extending to commercialized medical product services [1] - According to a report by Frost & Sullivan, Shanghai Shengsheng ranks first in the Chinese market for pharmaceutical and life sciences temperature-controlled supply chain services and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd.* 上海生生醫藥冷鏈科技股份有限公司 (the "Company") Hong Kong Exchanges and Clearing Limited and ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd.* 上海生生醫藥冷鏈科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員 會（「證監會」）的要求而刊發，僅用作提供資料予香港公眾人士。 閣下閱覽本公 告，即表示 閣下知悉、接納並向本公司、其聯席保薦人、保薦人兼整體協調 人、整體協調人、顧問或包銷團成員表示同意： 1 (a) 在聯交所網站登載本公告，並不引起本公司、其聯席保薦人、保薦人兼整體 協調人、整體協調人、顧問或包銷團成員須在香港或任何其他司法權區進行 發售或配售活動的任何責任。概不保證本公司將會進行發售或配售； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或拒 絕有關的公開發售及╱或上市申 ...

Core Insights - Chengdu International Railway Port Comprehensive Bonded Zone has achieved a milestone in the development of the pharmaceutical cold chain industry with Sichuan Lepu Kang Pharmaceutical Co., Ltd. obtaining a medical device business license, becoming the first bonded pharmaceutical enterprise in the zone with dual GSP certification for both drugs and medical devices [1][3] Group 1: Industry Development - The successful acquisition of GSP dual certification signifies a leap from non-existence to a fully functional pharmaceutical cold chain capability in the Chengdu International Railway Port Comprehensive Bonded Zone [1][4] - This development establishes a standardized, professional service capacity for pharmaceutical and medical device products, laying a solid foundation for creating a regionally influential pharmaceutical cold chain distribution center [1][4] Group 2: Regulatory and Operational Framework - GSP (Good Supply Practice) is a critical standard in the pharmaceutical industry that ensures the quality and safety of drugs and medical devices during circulation [3] - Lepu Kang has established a comprehensive and compliant management system across the entire supply chain, including procurement, storage, transportation, and sales, enabling the management of multiple categories and temperature zones of pharmaceutical products [3] Group 3: Future Prospects - The breakthrough in GSP dual certification not only enhances the company's qualifications but also represents an important practice in policy innovation within the bonded zone [4] - The development is expected to fill the gap in regional pharmaceutical bonded cold chain services, attracting more leading pharmaceutical companies and creating an industrial cluster effect [4] - The bonded zone plans to deepen its "bonded +" functions, expanding into pharmaceutical research and international distribution services, facilitating the transformation of Qingbaijiang from a traditional logistics hub to a high-value pharmaceutical supply chain center [4]